- Conditions
- Restless Legs Syndrome
- Interventions
- GEn 1200mg, Gen 6000 mg, GEn Placebo, Moxifloxacin Placebo, Moxifloxacin
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Neuralgia, Postherpetic
- Interventions
- GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day, Placebo
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Northport, Alabama • Chandler, Arizona + 65 more
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- bevacizumab, trastuzumab, oxaliplatin, capecitabine
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Neuralgia, Postherpetic
- Interventions
- GEn 1200mg/day, GEn 3600mg/day
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Oxnard, California • Roseville, California + 36 more
- Conditions
- Neuropathy, Diabetic
- Interventions
- Placebo, GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day, Pregabalin
- Drug
- Lead sponsor
- XenoPort, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 90
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 81 more